Ionis Pharmaceuticals Inc (IONS) Common Stock USD0.001

Sell:$32.71Buy:$32.79$0.16 (0.49%)

NASDAQ:0.21%
Prices delayed by at least 15 minutes
Sell:$32.71
Buy:$32.79
Change:$0.16 (0.49%)
Prices delayed by at least 15 minutes
Sell:$32.71
Buy:$32.79
Change:$0.16 (0.49%)
Prices delayed by at least 15 minutes

Company Information

About this company

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Key people

Brett P. Monia
Chief Executive Officer, Director
Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
Joseph T. Baroldi
Executive Vice President, Chief Business Officer
Richard S. Geary
Executive Vice President, Chief Development Officer
Kyle Jenne
Executive Vice President - commercial
Eugene Schneider
Executive Vice President, Chief Clinical Development and Operations Officer
Eric E. Swayze
Executive Vice President - Research
Patrick R. O'Neil
Chief Legal Officer, General Counsel and Corporate Secretary
Joseph Loscalzo
Independent Chairman of the Board
Joseph H. Wender
Lead Independent Director
B. Lynne Parshall
Director
Spencer R. Berthelsen
Independent Director
Allene M. Diaz
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US4622221004
  • Market cap
    $5.39bn
  • Employees
    927
  • Shares in issue
    157.90m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.